Trulieve Cannabis is trading 5.57% up at $8.91 as investors positioned ahead of the August 7, 2026, second-quarter earnings release and focused on the potential financial benefits of Schedule III treatment.
- Earnings preview highlighted reduced 280E-related tax pressure for medical cannabis operators.
- Analysts expect a profitable quarter.
- The move appears company-focused rather than driven by broad markets, which are mixed.